With a host of health insurance policies available in the market, buyers often get confused and do not know how to compare them. To curb this confusion and to encourage more people to buy health insurance, the Insurance Regulatory and Development Authority of India (Irdai) has mandated all general and health insurers to offer a standard individual health insurance product with a maximum sum insured of up to 5 lakh. Find the circular, which was issued last week.
The product will be named Arogya Sanjeevani followed by the insurers name. It will have to be made available starting 1 April 2020. Standardization of a product offering will help customers get a parity-based understanding of product benefits, simplifying the purchase decision. It leaves no room for ambiguity for the customer in terms of product comparison, since they are assured of the fact that other insurers do not offer a different coverage," said Anuj Gulati, managing director and chief executive officer, Religare Health Insurance Co. Ltd.
While a standard product will surely simplify health insurance for you, do keep in mind that this may not be the best product in the market. We give you the features and details of the new standard plan.
Like a typical health insurance plan, Arogya Sanjeevani will be an annual policy renewable for life and will pay for hospitalization expenses. This means costs incurred on the surgeon, anaesthetist, consultants, specialist fees, operation theatre charges, oxygen, surgical equipment, costs towards diagnostics and so on are covered too. Further, expenses incurred on hospitalization under the Ayush system of medicine will also be covered without any sub-limits. Pre-hospitalization (from 30 days prior to the date of admission) and post-hospitalization expenses (60 days from the date of discharge) will be included too.
The policy will also cover dental treatment and plastic surgery necessitated due to a disease or injury, all day-care treatments and expenses incurred on road ambulance. The ambulance expenses will be capped at 2,000 a day.
Anyone between 18 and 65 years can buy this product, but it cant be customized to your needs.
However, there are some important caveats to consider. The policy will cover room, boarding and nursing expenses but only up to 2% of the sum insured, subject to a maximum of 5,000 a day.
Gurdeep Singh Batra, head, retail underwriting, Bajaj Allianz General Insurance Co. Ltd, said the intention of the policy is to insure the non-insured population of the country, particularly in tier-2 and tier-3 cities, which is why the sum insured is capped at 5 lakh. Room rent makes for a large chunk of the hospitalization expense and not having a cap would push the premiums. Instead of a 1% cap, theyve capped it at 2% or 5,000, which is reasonable because in tier-2 and tier-3 cities, most nursing homes and hospitals offer good rooms within 5,000," said Batra.
The policy also covers expenses on intensive care unit (ICU) and intensive cardiac care unit (ICCU) facilities up to 5% of the sum insured, up to 10,000 a day.
The mandatory covers prescribed by Irdai are inclusive enough for a standard product but this could have been enhanced by increasing some of the limits restricting the coverage such as cap on room rent, pre- and post-hospitalization expenses, and restricting ambulance charges up to 2,000 per hospitalization. Existing products offered by insurers offer flexibility and superior covers with no capping on room rent or a cover for more number of pre- and post-hospitalization days along with higher limits for ambulance," said Biresh Giri, appointed actuary, head of product development and chief risk officer, Acko General Insurance Ltd.
The product will come with a fixed co-pay of 5%, across all age groups. A 5% co-payment clause would mean that you will pay 5% of the claim amount and the insurer will pay the rest.
Theres also a limit on how much the policyholder can claim for cataract surgery. Irdai said, for each eye, expenses incurred on the treatment of cataract will be covered only up to 25% of the sum insured or 40,000, whichever is lower. Irdai has also listed the conditions that insurers shall cover after a prescribed waiting period.
What is positive about this policy is that it takes into account the ever-evolving healthcare ecosystem. The policy will cover modern treatments like stem cell therapy and balloon sinuplasty up to 50% of the sum insured. This (including modern treatments) is a good proposition from an insured viewpoint. Currently, other products are also being re-looked for such extended coverage in line with guidelines issued on standardization of exclusions in health insurance," said Batra.
Premiums and bonus
The regulator has allowed insurers to determine the price of the policy keeping in view the mandatory covers they would need to offer. Insurers, however, will have to comply with Irdai norms while doing so. Pricing for any insurer is a factor of risk assessment, estimated claims, consumer behaviour and long-term sustainability of the product.
The range of pricing should largely be similar for most insurers but its too soon to be sure, said Gulati.
While insurers are not allowed to offer any add-ons or optional covers with this product, they can package it in the form of a family floater plan where the premium is decided based on the age of the oldest member of the family. Giri said the premiums could start from 5,000 for an individual policy with a sum insured of 5 lakh and 15,000 for a family floater plan with a sum insured of 5 lakh.
Note that a cover of 5 lakh may not be sufficient for a whole family but is still better than having no insurance at all. For a floater policy, 5 lakh may not be adequate. Nevertheless, we have a huge untapped market where most people dont have any insurance and are paying out of their own pockets or not getting properly treated," said Prasun Sikdar, MD and CEO, ManipalCigna Health Insurance Co Ltd. Like other health products, policyholders will get the option of paying premiums on a monthly, quarterly, half-yearly and annual basis. The cumulative bonus on this product, according to Irdai, shall increase by 5% in respect of each claim-free year, subject to a maximum of 50% of the sum insured but only if the policy is renewed without a break. If a claim is made in any particular year, the bonus will decrease at the same rate at which it was accrued: 5%. Also, no deductibles are allowed.
Sikar said it is difficult to say whether premiums will drive this product or awareness campaigns by Irdai, or the brand name of the insurers. But this will definitely benefit the industry and increase penetration," he added. Batra said this product is specifically targeted towards the lower middle-income group where medical expenses, especially the cost of hospitalization is still lower than metro cities.
Experts also said that this may impact the retail health insurance business in the long run as it will bring more uniformity and standardized policy wordings, making it easier for customers to choose.
However, keep in mind that this policy suffers from two major setbacks: room rent capping and co-payment. While this may make the policy affordable, in case of a claim, you will have to shell out a part of the claim from your pocket. Given the low sum insured, this policy comes with restrictive clauses that also make it more affordable. Before you buy the new standard product, compare the premiums and choose the least restrictive option. If you havent bought a policy due to high premiums, this can be a good entry point. Whether the product will enhance the adoption of health insurance remains to be seen.
- Stem Cell Therapy Market Research Report by Cell Source, by Type, by Therapeutic Application, by End-User, by Region - Global Forecast to 2026 -... - October 16th, 2021
- Harvard's R&D alliance with Resilience to advance manufacture of complex medicines - Harvard Gazette - October 16th, 2021
- A New Line of Defense in Blood Cancer: Natural Killer Cell Therapy - Curetoday.com - October 16th, 2021
- Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL - OncLive - October 16th, 2021
- Rheumatoid Arthritis Stem Cell Therapy Market By Type (Allogeneic Mesenchymal Stem Cells, Bone Marrow Transplant, Adipose Tissue Stem Cells) and By... - October 16th, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress - Yahoo Finance - October 16th, 2021
- Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft - MedCity News - October 16th, 2021
- Dr. Erba on the Evolution of Treatment in MCL - OncLive - October 16th, 2021
- Newer Agents for DLBCL Show Potential for Earlier Use in the Course of Treatment - Targeted Oncology - October 16th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - Business Wire - October 16th, 2021
- Worldwide Cell Therapy Consumables Industry to 2031 - Featuring Bio-Techne, Irvine Scientific and Sartorius Among Others - PRNewswire - October 16th, 2021
- International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire - October 16th, 2021
- BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization -... - October 16th, 2021
- FTC Follows Through On Prioritizing Investigations Into False Advertising In Healthcare Markets - Media, Telecoms, IT, Entertainment - United States -... - October 16th, 2021
- Molecular Atlas of Small Cell Lung Cancer Reveals Unusual Cell Type That Could Explain Why Its So Aggressive - On Cancer - Memorial Sloan Kettering - October 16th, 2021
- Actress Jennifer Garner Visits with 7-Year-Old Girl Fighting B-cell Acute Lymphoblastic Leukemia; What is the Treatment for This Disease? -... - October 16th, 2021
- Four-year-old girl with stage four cancer trying to get to America for clinical trial - Lancashire Telegraph - October 16th, 2021
- Stem cell & gene therapy to treat osteogenesis imperfecta: hype or hope - Open Access Government - October 5th, 2021
- Chennai-based institute to begin clinical trial on stem cell therapy for liver disease - The New Indian Express - October 5th, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 5th, 2021
- Anja Health Disrupts Cord Blood Banking with Heartfelt Founding Story and Ground-Breaking Mission - Digital Journal - October 5th, 2021
- Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment - Yahoo Finance - October 5th, 2021
- Ready to Treat Over 80 Life-Threatening Diseases, Discover the Potential of Cord Blood during World Cord Blood Day 2021 - PRNewswire - October 5th, 2021
- Transforming Growth Factor Sales Gaining Traction & to reach US$ 709.9 Mn with Significant Development in Cell Therapy Research - PRNewswire - October 5th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WITN - October 5th, 2021
- Brazil investigates the use of stem cells in the treatment of covid-19 The Clare People - The Clare People - October 5th, 2021
- Indianapolis mother gives 13-year-old son with sickle cell disease a 2nd chance at life - WTHR - October 5th, 2021
- US FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | DNA RNA and... - October 5th, 2021
- Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com - October 5th, 2021
- 'Survivor' winner Ethan Zohn opens up about his cancer battle: I was a healthy, young guy. You never expect it to be you. - Yahoo Life - October 5th, 2021
- The Best Skincare Treatments For Time-Crunched Moms (Or Anyone Else Who Only Has Five Minutes To Spare) - Forbes - October 5th, 2021
- [PDF] Stem Cell Therapy Market Size Strong Revenue and Generated Opportunities UNLV The Rebel Yell - UNLV The Rebel Yell - August 31st, 2021
- Mike Tysons weird stem cell treatment has helped transform incredible body at 55 - Daily Star - August 31st, 2021
- Acute Monocytic Leukemia: Causes, Symptoms, and Treatment - Healthline - August 31st, 2021
- UC Davis and the School of Medicine set new records in research funding - UC Davis Health - August 31st, 2021
- NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network - August 31st, 2021
- DHEC Supports Awareness and Education during National Sickle Cell Awareness Month - SCDHEC - August 31st, 2021
- The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation - DocWire News - August 31st, 2021
- Global Cryopreservation Equipment Market Report 2021-2028 - Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking... - August 31st, 2021
- Operational Highlights and Financial Results for the Year Ended June 30, 2021 - GlobeNewswire - August 31st, 2021
- Event to benefit 2 families with kids fighting cancer - Youngstown Vindicator - August 31st, 2021
- Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market - GlobeNewswire - August 31st, 2021
- Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults... - August 31st, 2021
- Thomas Smeenk with an update on the FDA Phase II clinical trial program of the Hemostemix blood-derived, stem cell therapeutics product (ACP-01) -... - August 31st, 2021
- 2021 Pipeline Insight Report on Myocardial Infarction - Featuring AstraZeneca, Mesoblast and Boehringer Ingelheim Among Others -... - August 31st, 2021
- Mini brains grown in the lab sprout primitive eyes - Freethink - August 31st, 2021
- BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma - Business Wire - August 18th, 2021
- Study Calls for COVID-19 Vaccination in Patients With Cancer to Enable Optimal Treatment Delivery During Pandemic - OncLive - August 18th, 2021
- Treatment of AML in Older Patients Almost At 'The Holy Grail' - Curetoday.com - August 18th, 2021
- Animal Stem Cell Therapy Market Identify Key Drivers, Trends, Latest Innovations, Business Senario, Demand With Outlook by 2026 - The Market Writeuo -... - August 18th, 2021
- 8 Tips for Coping With a Diagnosis of PPMS - Everyday Health - August 18th, 2021
- More positive results from CRISPR trial for sickle cell and thalassaemia - BioNews - August 18th, 2021
- Belumosudil Granted Full Approval for Treatment of Chronic GVHD by FDA - Cancer Network - July 22nd, 2021
- Dr. Martin on the Role of Maintenance Therapy With Rituximab in MCL July 15th 2021 Peter - OncLive - July 22nd, 2021
- FDA tells Magenta to pump the brakes on blood cancer trial before it starts to develop new dosing test - FierceBiotech - July 22nd, 2021
- Stemson Therapeutics Secures $15M Series A Funding to Cure Hair Loss - Business Wire - July 22nd, 2021
- Events planned to support 5-year-old's cancer treatments - The Augusta Chronicle - July 22nd, 2021
- HER2-Specific CAR T Cells Induce Early Efficacy Without Dose-Limiting Toxicities in Pediatric CNS Tumors - OncLive - July 22nd, 2021
- A mother's love: Two years after devastating crash, Abby Roby has hope - London Free Press (Blogs) - July 22nd, 2021
- Roswell Park Team Shows Dendritic-Cell Vaccines Can Be Paired With Standard Therapy for Breast Cancer - Newswise - July 22nd, 2021
- Introducing the 3D bioprinted neural tissues with the potential to 'cure' human paralysis - 3D Printing Industry - July 22nd, 2021
- Investing in stem cells, the building blocks of the body - MoneyWeek - June 25th, 2021
- Discrepancies Between Real-World Patterns of Care and Recommendations Based on Clinical Trials Exist in MCL - OncLive - June 25th, 2021
- Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies - PR Web - June 25th, 2021
- Disparities in Utilization of Autologous Stem Cell Transplantation as Consolidative Therapy for Multiple Myeloma: A Single Institution Retrospective... - June 25th, 2021
- Vita Therapeutics Raises $32 Million in Oversubscribed Series A Financing Led by Cambrian Biopharma to Advance the Development of Therapies to Treat... - June 25th, 2021
- Updates in the treatment of peripheral T-cell lymphomas | JEP - Dove Medical Press - June 25th, 2021
- Novel Tafasitamab Combination Finds a Role in Second-line DLBCL Treatment - Targeted Oncology - June 25th, 2021
- Global Nerve Repair and Regeneration Devices Market to Reach $11. 8 Billion by 2026 - GlobeNewswire - June 25th, 2021
- 5 potential benefits of exosome treatment - AZ Big Media - June 8th, 2021
- Orion and the Blood Service launch collaboration to develop new CAR T-cell cancer therapy - Yahoo Finance Australia - June 8th, 2021
- Improvements in the Treatment of Patients With MCL Over the Past Decade - Oncology Learning Network - June 8th, 2021
- Novo Nordisk partners with Heartseed on heart failure cell therapy - PMLiVE - June 8th, 2021
- Citius Pharmaceuticals to be Added to Russell 2000 Index - BioSpace - June 8th, 2021
- IN8bio Completes Treatment of First Cohort in Phase 1 Clinical Trial with Gamma Delta T-Cell Therapy in Patients with Newly Diagnosed Glioblastoma... - June 8th, 2021
- Regenerative medicine: moving next-gen treatments from lab to clinic - Pharmaceutical Technology - June 8th, 2021
- Global $30+ Billion Cell Therapy Bioprocessing Market to 2028: Market Opportunities in Automated Procedures to Produce Cell Therapies - PRNewswire - June 8th, 2021
- Global Stem Cell & Regenerative Medicine Market Report Forecast to 2027 3M Group Novartis AG Integra Gene Therapies The Manomet Current - The... - June 8th, 2021
- Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma - Curetoday.com - June 8th, 2021
- BioRestorative Therapies to Present at the Emerging Growth Conference on June 9, 2021 - StreetInsider.com - June 8th, 2021